---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-075991"
form_type: "8-K"
ticker: null
cik: "0001785345"
company_name: "Landos Biopharma, Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:34:29.348598+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# AbbVie to acquire Landos Biopharma for $20.42/sh cash plus up to $11.14/sh CVR

## Summary
- Total upfront cash consideration ~$137.5M; CVR milestone of up to $75M for Phase 3 start of NX-13 in UC by March 2029.
- Landos stockholders holding ~57.6% of shares have agreed to vote in favor; deal expected to close Q2 2024.
- NX-13 is a first-in-class oral NLRX1 agonist currently in Phase 2 NEXUS trial for moderate-to-severe ulcerative colitis.
- CVRs are non-tradeable and contingent on initiating first Phase 3 trial for NX-13; no assurance milestone will be achieved.
- Termination fee of $7M payable by Landos under certain circumstances if deal fails or a superior proposal accepted.

## SEC filing metadata
- accession: 0001193125-24-075991
- form_type: 8-K
- cik: 0001785345
- company_name: Landos Biopharma, Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785345/000119312524075991/0001193125-24-075991-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785345/000119312524075991/d779916d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-075991
- JSON: https://secwatch.observer/filing/0001193125-24-075991.json
- Plain text: https://secwatch.observer/filing/0001193125-24-075991.txt

## Key facts
- Material Agreements
  Landos Biopharma, Inc. entered into Agreement and Plan of Merger with Bespin Subsidiary, LLC, Bespin Merger Sub, Inc., and AbbVie Inc. valued at $20.42 in cash per share plus one CVR representing $11.14 contingent cash per share (effective 2024-03-24).
  - Action: entry
  - Agreement: merger
  - Counterparty: Bespin Subsidiary, LLC, Bespin Merger Sub, Inc., and AbbVie Inc.
  - Value: $20.42 in cash per share plus one CVR representing $11.14 contingent cash per share
  - Effective: 2024-03-24
  source text: On March 24, 2024, Landos Biopharma, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Bespin Subsidiary, LLC, a Delaware corporation and a wholly owned Subsidiary of Guarantor (“Parent”), Bespin Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and solely for the limited purposes set forth therein, AbbVie Inc. (“AbbVie” or “Guarantor”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785345/000119312524075991/0001193125-24-075991-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.